Compare BIO & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | OWL |
|---|---|---|
| Founded | 1952 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.4B |
| IPO Year | N/A | N/A |
| Metric | BIO | OWL |
|---|---|---|
| Price | $322.33 | $15.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $358.50 | $21.70 |
| AVG Volume (30 Days) | 184.0K | ★ 10.9M |
| Earning Date | 02-12-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 5.77% |
| EPS Growth | N/A | ★ 47.85 |
| EPS | N/A | ★ 0.08 |
| Revenue | $2,557,500,000.00 | ★ $2,745,943,000.00 |
| Revenue This Year | $1.62 | $18.19 |
| Revenue Next Year | $2.26 | $19.13 |
| P/E Ratio | ★ N/A | $201.19 |
| Revenue Growth | N/A | ★ 27.24 |
| 52 Week Low | $211.43 | $13.25 |
| 52 Week High | $373.69 | $26.73 |
| Indicator | BIO | OWL |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 52.87 |
| Support Level | $316.57 | $15.06 |
| Resistance Level | $328.56 | $16.06 |
| Average True Range (ATR) | 8.27 | 0.53 |
| MACD | 1.43 | 0.01 |
| Stochastic Oscillator | 78.70 | 69.84 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Blue Owl Capital is one of the world's largest alternative-asset managers, $295.6 billion in total managed assets, including $183.8 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, (with $68.8 billion in total AUM and $40.2 billion in fee-earning AUM), private credit ($152.1 billion/$97.3 billion), and real estate/real assets ($74.7 billion/$46.3 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). The firm operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.